CROI 2014: early reports

4 March 2014. Related: News.

Simon Collins, HIV i-Base

CROI 2014 was held in Boston from 3-6 March 2014. Brief reports and notes from the meeting will be posted here as ahead of press articles for the next issue of HIV Treatment Bulletin (HTB).

Webcasts from the conference are now online. Some posters are also available online as PDF files.
www.croi2014.org

Unfortunately, abstracts from the conference are no yet online as html pages and can only be accessed by downloading a PDF file of the abstract book:
CROI 2014 abstract book (PDF download)

First reports

Our first reports from CROI 2014 are now published online in the March/April issue of HTB.

• No HIV transmissions with undetectable viral load: interim PARTNER study results show need for longer follow-up

• PrEP injections every three months may protect against exposure from anal sex

• ARV pipeline: doravirine, GSK-744 and BMS-068

• Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study

• Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r

• Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257

• Pharmacokinetic targets for efavirenz might be too high

• Abacavir link to cardiovascular events in high-risk patients maintained in D:A:D study

• NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs

• HIV related infections remain the leading cause of maternal deaths in South Africa despite the availability of ART

• Lower newborn bone mineral content with maternal tenofovir use

• Paediatric pipeline: CROI 2014 update on new antiretrovirals for children

• Efavirenz maintenance therapy effective in children exposed to nevirapine prophylaxis

• Xpert TB test doesn’t reduce morbidity but it does have important advantages

• Reports of a second baby possibly cured of HIV: uncertainty remains

• Updates on SB728-T, a CCR5-targeting gene therapy

New pre-press reports

Additional reports will continue to be posted to this page as they become available.

Sugar-daddies not linked to higher risk for HIV

An example from South Africa of why prevention campaigns to be evidence-based.

Read the full report…